Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675988 | 0.84 | DPP4 (0.38) | PDE1BPDE2APDE4DPDE1APDE1C | |
| SCHEMBL676382 | 0.82 | PDE1B (0.48) | PDE1BPDE2APDE4DPDE1APDE1C | |
| SCHEMBL680333 | 0.80 | PDE1B (0.43) | PDE1BPDE2APDE4DPDE1APDE1C | |
| SCHEMBL7448044 | 0.70 | CNR1 (0.42) | ALDH1A1PDE1BPDE2APDE4DTSHR | |
| SCHEMBL8045647 | 0.69 | PDE1B (0.64) | SMN1; SMN2ALDH1A1PDE1BPDE2APDE4D | |
| SCHEMBL676509 | 0.68 | DPP4 (0.39) | SMN1; SMN2ALDH1A1PDE1BPDE2APDE4D | |
| SCHEMBL675773 | 0.68 | USP1 (0.42) | PDE1BPDE2APDE4DCYP3A4 | |
| SCHEMBL674792 | 0.68 | DPP4 (0.38) | SMN1; SMN2ALDH1A1PDE1BPDE2APDE4D | |
| SCHEMBL17507917 | 0.68 | PDE2A (0.42) | PDE1BPDE2APDE4D | |
| SCHEMBL676380 | 0.66 | PDE1B (0.49) | PDE1BPDE2APDE4DPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | SMN1; SMN2 3003/4885ALDH1A1 216/4885PDE1B 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.